<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548210" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548210/" /><meta name="ncbi_pagename" content="Zidovudine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Zidovudine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Zidovudine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/06/25" /><meta name="citation_pmid" content="31643535" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548210/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Zidovudine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/06/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548210/" /><meta name="description" content="Zidovudine is a nucleoside analogue and reverse transcriptase inhibitor used in combination with other agents in the therapy and prophylaxis of the human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Zidovudine is a rare, but well established cause of clinically apparent acute and chronic liver injury." /><meta name="og:title" content="Zidovudine" /><meta name="og:type" content="book" /><meta name="og:description" content="Zidovudine is a nucleoside analogue and reverse transcriptase inhibitor used in combination with other agents in the therapy and prophylaxis of the human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Zidovudine is a rare, but well established cause of clinically apparent acute and chronic liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548210/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Zidovudine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548210/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B2F570468FBE10000000001E60093.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548210_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548210_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Zepatier/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Zileuton/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548210_"><span class="title" itemprop="name">Zidovudine</span></h1><p class="small">Last Update: <span itemprop="dateModified">June 25, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Zidovudine.OVERVIEW"><h2 id="_Zidovudine_OVERVIEW_">OVERVIEW</h2><div id="Zidovudine.Introduction"><h3>Introduction</h3><p>Zidovudine is a nucleoside analogue and reverse transcriptase inhibitor used in combination with other agents in the therapy and prophylaxis of the human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Zidovudine is a rare, but well established cause of clinically apparent acute and chronic liver injury.</p></div><div id="Zidovudine.Background"><h3>Background</h3><p>Zidovudine (zye doe' vue deen) is a synthetic analogue of thymidine (3&#x02019;-azido-3&#x02019;- deoxythymidine: AZT) that is phosphorylated intracellularly and then acts in competing with the natural substrate, thymidine triphosphate, for incorporation into growing HIV DNA chain causing inhibition of the viral reverse transcriptase and chain termination. Zidovudine was the first antiretroviral agent that was approved for use in treating HIV infection in the United States [1987] and was subsequently frequently used in antiretroviral regimens for many years. Recently, zidovudine has been replaced by better tolerated nucleoside analogues and it is no longer commonly used in developed countries. Zidovudine is currently indicated for the treatment of HIV infection in combination with other HIV medications such as lamivudine and abacavir. Zidovudine is available as a single agent in multiple generic forms and under the trade name Retrovir in 100 mg capsules, 300 mg tablets, and as an oral syrup; in combination with lamivudine generically or as Combivir; and in combination with abacavir and lamivudine generically or as Trizivir. The recommended dose of zidovudine in adults is 300 mg orally twice daily or 1 mg/kg every 4 hours. Common side effects include asthenia, constipation, headache, insomnia, loss of appetite, malaise, nausea, and vomiting. Less common but potentially severe adverse events include lactic acidosis, pancreatitis, peripheral neuropathy, myopathy, anemia and neutropenia, and hypersensitivity reactions including Stevens Johnson syndrome.</p></div><div id="Zidovudine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Chronic therapy with zidovudine is associated with modest serum enzyme elevations that are generally transient and asymptomatic and do not require dose modification. In prospective studies, 1 to 3% of recipients have developed <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations above 5 times the upper limit of normal. The abnormalities, however, may be related to other underlying conditions such as hepatitis B or C and triggered by reconstitution syndrome.</p><p>Several forms of clinically apparent liver injury have been associated with zidovudine therapy: an acute cholestatic hepatitis, severe acute fatty liver and with lactic acidosis, and a chronic liver injury that presents with noncirrhotic portal hypertension, most likely due to nodular regenerative hyperplasia.</p><p>Rare instances of idiosyncratic cholestatic hepatitis have been reported with zidovudine therapy, typically arising within 1 to 4 weeks of starting treatment (Case 1). The liver injury is usually mild to moderate in severity and self-limited in course. Immunoallergic and autoimmune features are not common.</p><p>In addition, zidovudine has been associated with instances of severe hepatic steatosis and lactic acidosis. The liver injury typically arises after 2 to 6 months of therapy with prodromal symptoms of nausea, vomiting, anorexia and weakness, followed by dyspnea, jaundice and confusion. Lactic acid levels are elevated and metabolic acidosis may be severe and progressive. Serum enzymes are only modestly elevated and may initially be normal. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.jaundice/">Jaundice</a> and signs of liver dysfunction develop late, but can eventually be associated with acute hepatic failure and death. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.liver-histology/">Liver histology</a> shows marked steatosis which is initially microvesicular and later macrovesicular and associated with cholestasis. In progressive cases, fibrosis and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.mallory-bodies/">Mallory bodies</a> are found. Similar cases occur with didanosine and stavudine which are more frequent causes of this syndrome. Risk factors for mitochondrial injury due to zidovudine include female sex, older age, preexisting liver disease, obesity, alcohol use and concurrent use of other di-deoxynucleosides.</p><p>Finally, long term therapy with zidovudine and other first generation nucleoside analogues has been associated with development of noncirrhotic portal hypertension. Symptoms are typically suggestive of cirrhosis, with fatigue, weight loss, ascites and/or variceal hemorrhage, but liver histology shows little or no fibrosis. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.jaundice/">Jaundice</a> is uncommon. Laboratory testing demonstrates minor elevations in serum aminotransferase and alkaline phosphatase levels but normal levels of serum bilirubin, albumin and INR. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.splenomegaly/">Splenomegaly</a> is common and thrombocytopenia is often the first manifestation of the hepatic abnormalities. Liver biopsies can be deceptively benign, with scant fibrosis and minor nonspecific changes. The disturbed hepatic architecture may not be obvious unless reticulum stains are done that show the typical nodularity and two-cell thick plates characteristic of nodular regeneration. The cause of nodular regenerative hyperplasia is not known but is suspected to be due to chronic vascular injury to the small veins and arterioles in portal areas.</p><p>Likelihood score: B (likely cause of clinically apparent acute and chronic liver disease).</p></div><div id="Zidovudine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the microvesicular fat and hepatic failure with lactic acidosis appears to be due to inhibition of the mitochondrial gamma polymerase by zidovudine leading to mitochondrial depletion and dysfunction. Similar mitochondrial injury may occur in the pancreas causing pancreatitis, in muscle causing myopathy and in peripheral nerves causing neuropathy. The cause of other forms of clinically apparent liver injury due to zidovudine is unknown, but hypersensitivity may play a role. A similar mechanism may underlie the chronic liver injury from zidovudine which results in noncirrhotic portal hypertension. Genetic studies of children with inherited forms of noncirrhotic portal hypertension have shown homozygous mutations in genes involved with purine synthesis that are important in mitochondrial replication and integrity.</p></div><div id="Zidovudine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The severity of liver injury caused by zidovudine ranges from mild and transient enzyme elevations to severe fatty liver, hepatic failure and lactic acidosis leading to death. In milder instances when the agent is withdrawn early, recovery occurs but is typically slow, requiring 1 to 3 months before return of liver enzymes and lactate levels to normal. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.rechallenge/">Rechallenge</a> may lead to recurrence and should be avoided. Patients should also avoid exposure to the other nucleoside analogues linked to this syndrome, particularly didanosine and stavudine. Various interventions have been used in attempts to treat the severe lactic acidosis and hepatic steatosis induced by nucleoside analogues. These interventions have included bicarbonate infusions, thiamine, l-carnitidine as well as renal dialysis and mechanical ventilation. Intravenous 20% glucose decreases lactic acid levels in some patients. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.liver-transplantation/">Liver transplantation</a> has reversed lactic acidosis in the rare patient that has undergone emergency transplantation, but this option is rarely practical.</p><p><a class="def" href="/books/n/livertox/glossary/def-item/glossary.nodular-regenerative-hyperplasia/">Nodular regenerative hyperplasia</a> is a long term complication of zidovudine therapy and generally improves once the agent is withdrawn and the patient switched to other antiretroviral agents. Therapy is generally directed at control of the complications of portal hypertension, including esophageal varices, ascites and hepatic encephalopathy. Patients with this complication should not receive first generation nucleoside analogues (didanosine, stavudine, zidovudine). Severe intercurrent medical conditions such as pneumonia or sepsis can cause worsening of the portal hypertension and signs and symptoms of hepatic decompensation (jaundice, worsening ascites, hepatic encephalopathy).</p><p>Drug Class: <a href="/books/n/livertox/AntiviralAgents/">Antiviral Agents</a>, Antiretroviral Agents</p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/NucleosideAnalogues/">Nucleoside Analogues</a>: <a href="/books/n/livertox/Abacavir/">Abacavir</a>, <a href="/books/n/livertox/Adefovir/">Adefovir</a>, <a href="/books/n/livertox/Didanosine/">Didanosine</a>, <a href="/books/n/livertox/Emtricitabine/">Emtricitabine</a>, <a href="/books/n/livertox/Entecavir/">Entecavir</a>, <a href="/books/n/livertox/Lamivudine/">Lamivudine</a>, <a href="/books/n/livertox/Stavudine/">Stavudine</a>, <a href="/books/n/livertox/Telbivudine/">Telbivudine</a>, <a href="/books/n/livertox/Tenofovir/">Tenofovir</a></p></div></div><div id="Zidovudine.CASE_REPORTS"><h2 id="_Zidovudine_CASE_REPORTS_">CASE REPORTS</h2><div id="Zidovudine.Case_1_Cholestatic_hepatitis"><h3>Case 1. Cholestatic hepatitis due to zidovudine.(<a class="bk_pop" href="#Zidovudine.REF.1">1</a>)</h3><p>A 39 year old man with HIV and AIDS was started on zidovudine and developed fever and abdominal pain 5 days later. Serum enzymes were minimally elevated, but bilirubin was normal. Zidovudine was stopped, but he required hospitalization 6 days later because of worsening abdominal pain, jaundice and fever. At this point, serum bilirubin was 7.9 mg/dL and both <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and alkaline phosphatase were several fold elevated (Table). Rash and eosinophilia were not mentioned. Ultrasound of the liver showed no evidence of biliary obstruction. Serum tests for hepatitis A and B were normal. He drank little alcohol and had no known exposures to hepatitis. He improved on no specific therapy and was discharged; liver tests abnormalities resolved within 4 weeks. He was then restarted on zidovudine at a reduced dose. Seven days later he redeveloped fever and abdominal pain and liver tests were again abnormal. Zidovudine was stopped and all abnormalities resolved within 4 weeks. He subsequently had no further evidence of liver disease, but died of AIDS-related complications approximately one-and-a-half years later.</p><div id="Zidovudine.Key_Points"><h4>Key Points</h4><div id="Zidovudine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548210/table/Zidovudine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Zidovudine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Zidovudine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Zidovudine.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zidovudine (100 mg five times daily)</td></tr><tr><th id="hd_b_Zidovudine.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Zidovudine.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholestatic (R=0.7)</td></tr><tr><th id="hd_b_Zidovudine.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Zidovudine.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+</td></tr><tr><th id="hd_b_Zidovudine.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Zidovudine.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-6 days</td></tr><tr><th id="hd_b_Zidovudine.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Zidovudine.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 weeks</td></tr><tr><th id="hd_b_Zidovudine.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Zidovudine.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Trimethoprim-sulfamethoxazole, dicyclomine</td></tr></tbody></table></div></div></div><div id="Zidovudine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Zidovudine.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548210/table/Zidovudine.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Zidovudine.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Zidovudine.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Zidovudine.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Zidovudine.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a>*<br />(U/L)</th><th id="hd_h_Zidovudine.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P*<br />(U/L)</th><th id="hd_h_Zidovudine.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>*<br />(mg/dL)</th><th id="hd_h_Zidovudine.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">49</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">184</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1 hd_h_Zidovudine.Td_1_1_1_2 hd_h_Zidovudine.Td_1_1_1_3 hd_h_Zidovudine.Td_1_1_1_4 hd_h_Zidovudine.Td_1_1_1_5 hd_h_Zidovudine.Td_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:center;vertical-align:top;">Zidovudine (200 mg every 6 hours) given for 7 days</td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">31</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">126</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">182</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">828</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.8</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">256</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1587</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5.7</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">238</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1564</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.7</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">168</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1173</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">70</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">782</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 days</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">38</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">368</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">288</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.5</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1 hd_h_Zidovudine.Td_1_1_1_2 hd_h_Zidovudine.Td_1_1_1_3 hd_h_Zidovudine.Td_1_1_1_4 hd_h_Zidovudine.Td_1_1_1_5 hd_h_Zidovudine.Td_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:center;vertical-align:top;">Zidovudine (100 mg every 6 hours) restarted for 7 days</td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">88</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">633</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 week</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">42</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">380</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">24</td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">126</td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Zidovudine.Td_1_1_1_1 hd_h_Zidovudine.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Zidovudine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;35</b></td><td headers="hd_h_Zidovudine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Zidovudine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Zidovudine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>* </dt><dd><div id="Zidovudine.TF.d.1"><p class="no_margin">Estimated from Figure and converted from times upper limit of normal to specific values based upon normal values shown.</p></div></dd></dl></div></div></div></div><div id="Zidovudine.Comment"><h4>Comment</h4><p>Case of cholestatic hepatitis with short latency (&#x0003c;1 week) induced by zidovudine. The injury had a prodrome of fever and abdominal pain arising after 5 days of therapy that preceded the elevations in liver enzymes and serum bilirubin. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.jaundice/">Jaundice</a> arose several days after zidovudine was stopped, serum bilirubin peaking 1 week later. The article did not mention skin rash, lymphadenopathy, lymphocytosis or eosinophilia, but the abrupt onset and presence of fever suggested an immunoallergic cause. The recurrence of cholestatic liver enzyme elevations on reexposure to zidovudine strengthened the association of the liver injury with this drug. The importance of zidovudine in therapy of HIV infection at the time of this clinical report justified the rechallenge effort to exonerate zidovudine as the cause of the liver injury.</p></div></div><div id="Zidovudine.Case_2_Lactic_acidosis_with_s"><h3>Case 2. Lactic acidosis with severe hepatic steatosis due to zidovudine therapy.(<a class="bk_pop" href="#Zidovudine.REF.2">2</a>)</h3><p>A 48 year old man with HIV and AIDS on long term zidovudine therapy developed nausea, abdominal pain and dyspnea. He had severe lactic acidosis with a bicarbonate level of 5 mg/dL, and serum lactate of 20.2 mmol/L (normal &#x0003c;3.0). Liver tests showed <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 109 U/L and alkaline phosphatase of 207 U/L. His liver tests had previously been normal. He tested negative for serological evidence of hepatitis B or C. Other medications which he had been taking chronically included ranitidine and trimethoprim-sulfamethoxazole. After admission, he worsened rapidly with progressive obtundation, respiratory failure and intractable metabolic acidosis. An autopsy showed a massive liver (3.7 kg) with both macro- and microvesicular fatty change.</p><div id="Zidovudine.Key_Points_1"><h4>Key Points</h4><div id="Zidovudine.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548210/table/Zidovudine.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Zidovudine.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Zidovudine.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Zidovudine.Te_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zidovudine</td></tr><tr><th id="hd_b_Zidovudine.Te_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Zidovudine.Te_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mild elevations only</td></tr><tr><th id="hd_b_Zidovudine.Te_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Zidovudine.Te_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5+ (fatal lactic acidosis and hepatic failure)</td></tr><tr><th id="hd_b_Zidovudine.Te_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Zidovudine.Te_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Several years</td></tr><tr><th id="hd_b_Zidovudine.Te_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Zidovudine.Te_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><th id="hd_b_Zidovudine.Te_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Zidovudine.Te_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Trimethoprim-sulfamethoxazole, ranitidine</td></tr></tbody></table></div></div></div><div id="Zidovudine.Comment_1"><h4>Comment</h4><p>Severe but typical course of lactic acidosis with microvesicular fatty liver that can occur with nucleoside analogue therapy. Despite the severity of the liver involvement, serum enzyme elevations may be normal or only modestly elevated. Initial signs of hepatic synthetic failure may be fall of albumin or rising prothrombin time and hepatic encephalopathy. Frequently, as in this case, lactic acidosis is the major clinical problem and cause of multiorgan failure. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.pancreatitis/">Pancreatitis</a> can also complicate the course of nucleoside analogue induced mitochondrial injury and may be the immediate cause of death. The underlying pathogenesis of this form of hepatotoxicity appears to be mitochondrial injury or depletion caused by inhibition of the mitochondrial gamma polymerase which is responsible for replication of mitochondria DNA. Different nucleoside analogues have different degrees of likelihood of causing mitochondrial toxicity: fialuridine &#x0003e;&#x0003e; stavudine, zalcitabine and didanosine &#x0003e; zidovudine &#x0003e;&#x0003e; lamivudine, abacavir, emtricitabine, telbivudine, tenofovir, adefovir and entecavir (the last group may not cause this syndrome at all). In addition, different nucleoside analogues appear to cause different degrees of mitochondrial injury in different tissues. Thus, myopathy and neuropathy are most frequent with zidovudine, pancreatitis with didanosine and stavudine, and lactic acidosis with microvesicular fatty liver with fialuridine.</p></div></div></div><div id="Zidovudine.PRODUCT_INFORMATION"><h2 id="_Zidovudine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Zidovudine &#x02013; Generic, Retrovir&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiviral Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=zidovudine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Zidovudine.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Zidovudine_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Zidovudine.Tf" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548210/table/Zidovudine.Tf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Zidovudine.Tf_lrgtbl__"><table><tbody><tr><th id="hd_b_Zidovudine.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Zidovudine.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_b_Zidovudine.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Zidovudine.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Zidovudine.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zidovudine</td><td headers="hd_b_Zidovudine.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134999198" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">30516-87-1</a></td><td headers="hd_b_Zidovudine.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C10-H13-N5-O4</td><td headers="hd_b_Zidovudine.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134999198" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134999198" alt="image 134999198 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Zidovudine.CITED_REFERENCES"><h2 id="_Zidovudine_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Zidovudine.REF.1">Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>1989;<span class="ref-vol">110</span>:85.</span> [<a href="/pubmed/2908831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2908831</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="Zidovudine.REF.2">Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. <span><span class="ref-journal">Am J Gastroenterol. </span>1995;<span class="ref-vol">90</span>:1433–6.</span> [<a href="/pubmed/7661164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7661164</span></a>]</div></dd></dl></div><div id="Zidovudine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Zidovudine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 25 June 2020</p><p>Abbreviations used: AIDS, acquired immune deficiency syndrome; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPA, hepatoportal sclerosis; HVPG, hepatic venous pressure gradient; mt, mitochondrial; NASH, nonalcoholic steatohepatitis; NCPH, noncirrhotic portal hypertension; NRH, nodular regenerative hyperplasia; TE, transient elastography.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Zidovudine.REF.n__ez.2013">N&#x000fa;&#x000f1;ez M. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 505-18.<div><i>(Review of hepatotoxicity of antiviral agents including zidovudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.flexner.2018">Flexner C. Antiretroviral agents and treatment of HIV infection. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1137-58.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.national_institutes_of_health">National Institutes of Health. <a href="https://aidsinfo.nih.gov/guidelines" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://aidsinfo<wbr style="display:inline-block"></wbr>​.nih.gov/guidelines</a>.<div><i>(Clinical guidelines on the use of antiretroviral agents in HIV-1 infected adults, adolescents and children).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.richman.1987.192">Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. <span><span class="ref-journal">N Engl J Med. </span>1987;<span class="ref-vol">317</span>:192–7.</span> [<a href="/pubmed/3299090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3299090</span></a>]<div><i>(Controlled trial in 282 patients with AIDs reported that rates of serum enzyme elevations were similar in placebo as zidovudine-treated patients).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.melamed.1987.2063">Melamed AJ, Muller RJ, Gold JW, Campbell SW, Kleinberg MI, Armstrong D. Possible zidovudine-induced hepatotoxicity. <span><span class="ref-journal">JAMA. </span>1987;<span class="ref-vol">258</span>:2063.</span> [<a href="/pubmed/3477654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3477654</span></a>]<div><i>(3 of 28 patients with HIV infection developed liver test abnormalities 2-3 weeks after starting zidovudine [AST of 161, 196 and 684 U/L, Alk P of 112 and 351 U/L], resolving rapidly with stopping and not recurring with reexposure: no mention of bilirubin or symptoms).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.dubin.1989.85">Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>1989;<span class="ref-vol">110</span>:85.</span> [<a href="/pubmed/2908831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2908831</span></a>]<div><i>(39 year old man with HIV and AIDS developed fever and abdominal pain 7 days after starting zidovudine [bilirubin 6.5 mg/dL, ALT 122 U/L, Alk P 598 U/L], resolving rapidly with stopping and recurring within 7 days upon restarting: Case 1).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.jolliet.1990.1457">Jolliet P, Widman JJ. Reye&#x02019;s syndrome in adult with AIDS. <span><span class="ref-journal">Lancet. </span>1990;<span class="ref-vol">335</span>:1457.</span> [<a href="/pubmed/1972225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1972225</span></a>]<div><i>(26 year old woman with HIV infection on zidovudine for 1 year developed fever and cough and was given aspirin [3 g/day], developed lethargy and abnormal liver tests 12 days later with progressive liver failure and death; macrovesicular fat considered typical of Reyes syndrome found on liver biopsy).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.hochster.1990.111">Hochster H, Dieterich D, Bozzette S, Reichman RC, Connor JD, Liebes L, Sonke RL, et al.  Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. <span><span class="ref-journal">Ann Intern Med. </span>1990;<span class="ref-vol">113</span>:111–7.</span> [<a href="/pubmed/2163228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2163228</span></a>]<div><i>(40 patients with HIV and CMV infection were treated with zidovudine and intravenous ganciclovir; anemia and neutropenia were common; 1 patient developed hepatitis thought to be zidovudine related, resolving on stopping and recurring on restarting zidovudine [timing and details not given]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.kahn.1992.581">Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou S-H, Broom M, et al.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. <span><span class="ref-journal">N Engl J Med. </span>1992;<span class="ref-vol">327</span>:581–7.</span> [<a href="/pubmed/1353607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1353607</span></a>]<div><i>(913 patients with HIV infection on zidovudine were randomized to switch to didanosine [500 or 750 mg/day] or continue zidovudine; pancreatitis occurred in 7% and 13% of didanosine, but only 3% of zidovudine-treated patients; no mention of ALT levels of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF12">Division of AIDS, National Institute of Allergy and Infectious Diseases. Table for grading severity of adult adverse experiences. Version 1.0, Clarification August 2009. Website accessed November 2011. <a href="http://www.docstoc.com/docs/42821660/DAIDS-Toxicity-Table" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.docstoc.com<wbr style="display:inline-block"></wbr>​/docs/42821660/DAIDS-Toxicity-Table</a>.<div><i>(Tables for grading ALT, AST, Alk P and bilirubin elevations for the AIDS Clinical Trials Group, all expressed as upper limits of normal [ULN]; for ALT, AST, Alk P and GGT: grade 1 [mild]=1.25-2.5; grade 2 [moderate]=2.6-5.0; grade 3 [severe]=5.1-10.0; and grade 4 [potentially life-threatening]=&#x0003e;10.0 times ULN).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.chen.1992.109">Chen SC, Barker SM, Mitchell DH, Stevens SM, O&#x02019;Neill P, Cunningham AL. Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus(HIV) infection. <span><span class="ref-journal">Pathology. </span>1992;<span class="ref-vol">24</span>:109–11.</span> [<a href="/pubmed/1641255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1641255</span></a>]<div><i>(38 year old man with AIDS on zidovudine for 4 months developed muscle and abdominal pain [bilirubin 0.8 mg/dL, ALT, 115 U/L, Alk P 62 U/L, CPK 1926 U/L], liver biopsy showing macrovesicular steatosis and abnormalities, resolving within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.gradon.1992.317">Gradon JD, Chapnik EK, Sepkowitz DV. Zidovudine-induced hepatitis. <span><span class="ref-journal">J Intern Med. </span>1992;<span class="ref-vol">231</span>:317–8.</span> [<a href="/pubmed/1556529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1556529</span></a>]<div><i>(38 year old man developed tender hepatomegaly 3 months after starting zidovudine and dapsone [bilirubin 2.0 mg/dL, ALT 120 U/L, Alk P 104 U/L], worsening in next 4 weeks despite stopping dapsone [bilirubin 9.7 mg/dL, ALT 873 U/L], but rapidly resolving within 10 days of stopping zidovudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.shriner.1992.94">Shriner K, Goetz M. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. <span><span class="ref-journal">Am J Med. </span>1992;<span class="ref-vol">93</span>:94–6.</span> [<a href="/pubmed/1626578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1626578</span></a>]<div><i>(31 year old man with AIDS, malnutrition and pancreatitis on long term zidovudine and TMP/SMS developed fever, rash, cellulitis and marked ALT elevations 3 days after starting iv cephalothin and receiving 3.3 g of acetaminophen [bilirubin 1.2 mg/dL], resolving rapidly upon stopping, but role of zidovudine unlikely).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.chattha.1993.37">Chattha G, Arieff AI, Cumings G, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. <span><span class="ref-journal">Ann Intern Med. </span>1993;<span class="ref-vol">118</span>:37–9.</span> [<a href="/pubmed/8416156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8416156</span></a>]<div><i>(Report of 7 patients with HIV infection who developed lactic acidosis of unknown cause who presented with nausea, anorexia and weight loss followed by dyspnea, stupor and death [in 4]; 4 on zidovudine, 1 ganciclovir and 1 clofazimine; initial arterial pH 7.09-7.27, lactate 10.4-17.4 mmol/L).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.shintaku.1993.464">Shintaku M, Nasu K, Shimizu T. Fulminant hepatic failure in an AIDS patient: possible zidovudine-induced hepatotoxicity. <span><span class="ref-journal">Am J Gastroenterol. </span>1993;<span class="ref-vol">88</span>:464–6.</span> [<a href="/pubmed/8438867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8438867</span></a>]<div><i>(38 year old man with hemophilia and HIV-HBV coinfection developed jaundice within 3 weeks of starting zidovudine [bilirubin 6.0 mg/dL, ALT 2,267 U/L], progressing to hepatic failure and death, with autopsy showing massive necrosis and cirrhosis; cause unclear, but possibly due to immune reconstitution and acute reactivation of hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.freiman.1993.379">Freiman JP, Helfert KE, Hammrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. <span><span class="ref-journal">AIDS. </span>1993;<span class="ref-vol">7</span>:379–85.</span> [<a href="/pubmed/8471200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8471200</span></a>]<div><i>(8 patients with HIV who developed severe hepatomegaly and marked steatosis which was associated with hepatic failure and lactic acidosis, 6 being fatal and 2 with recovery; all had received zidovudine, but for varying periods and often stopped well before onset of symptoms from hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.le_bras.1994.716">Le Bras P, D&#x02019;Oiron R, Quertainmont Y, Halfon P, Caquet R. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? <span><span class="ref-journal">AIDS. </span>1994;<span class="ref-vol">8</span>:716–7.</span> [<a href="/pubmed/8060560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8060560</span></a>]<div><i>(32 year old man with hemophilia and HIV infection developed severe myopathy and fatty liver 8 months after starting zidovudine [CPK 1138 U/L and mild lactic acidosis], resolving with stopping drug).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.mckenzie.1995.1099">McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. <span><span class="ref-journal">N Engl J Med. </span>1995;<span class="ref-vol">333</span>:1099–105.</span> [<a href="/pubmed/7565947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7565947</span></a>]<div><i>(Description of syndrome of lactic acidosis, hepatic failure and pancreatitis arising after 8-11 weeks of fialuridine treatment in 15 patients with chronic hepatitis B; among 7 patients affected, 5 died of intractable lactic acidosis and 2 survived but required emergency liver transplantation).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.lewis.1995.417">Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. <span><span class="ref-journal">Nat Med. </span>1995;<span class="ref-vol">1</span>:417–22.</span> [<a href="/pubmed/7585087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7585087</span></a>]<div><i>(Review of mechanisms for mitochondrial injury by nucleoside analogues including inhibition of mitochondrial DNA polymerase gamma).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.styrt.1995.839">Styrt B, Freiman JP. Hepatotoxicity of antiviral agents. <span><span class="ref-journal">Gastroenterol Clin North Am. </span>1995;<span class="ref-vol">24</span>:839–52.</span> [<a href="/pubmed/8749901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8749901</span></a>]<div><i>(Early review of liver toxicity of antiviral agents; covering the first four nucleoside analogues used for HIV infection, zidovudine, didanosine, zalcitabine and stavudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.wassef.1995.1387">Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case of anaphylaxis and review of the literature. <span><span class="ref-journal">Clin Infect Dis. </span>1995;<span class="ref-vol">20</span>:1387–9.</span> [<a href="/pubmed/7620029" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7620029</span></a>]<div><i>(41 year old man with HIV infection, developed weakness and confusion 1 hour after a second dose of zidovudine with erythema, facial swelling and fever [ALT 157 U/L], resolving within 48 hours of stopping and recurring within 1 hour of single dose rechallenge with zidovudine; no mention of jaundice).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.fortgang.1995.1433">Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. <span><span class="ref-journal">Am J Gastroenterol. </span>1995;<span class="ref-vol">90</span>:1433–6.</span> [<a href="/pubmed/7661164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7661164</span></a>]<div><i>(Retrospective review of 1836 patients treated for HIV infection found 322 [18%] with liver abnormalities and two [1.3 per 1000 person-years] with fatal lactic acidosis and fatty liver, both on zidovudine only).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.olano.1995.973">Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. <span><span class="ref-journal">Clin Infect Dis. </span>1995;<span class="ref-vol">21</span>:973–6.</span> [<a href="/pubmed/8645849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8645849</span></a>]<div><i>(35 year old woman developed nausea, vomiting and weakness 5 months after starting zidovudine [bilirubin 0.9 mg/dL, ALT 85 U/L, Alk P 85 U/L], worsening over next week with severe lactic acidosis and pancreatitis despite stopping zidovudine promptly; autopsy showed massively enlarged liver [3.6 kg] with marked steatosis, but little inflammation or necrosis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.aggarwal.1996.929">Aggarwal A, al Talib K, Alabrash M. Type B lactic acidosis in an AIDS patient treated with zidovudine. <span><span class="ref-journal">Md Med J. </span>1996;<span class="ref-vol">45</span>:929–31.</span> [<a href="/pubmed/8942169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8942169</span></a>]<div><i>(33 year old woman with HIV infection developed anorexia, weight loss, and tachypnea 9 months after starting zidovudine [lactate 16.3 mmol/L, pH 7.3 falling to 7.0, CT showing fatty liver, enzymes and bilirubin not given], dying of progressive lactic acidosis 3 days later).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.henry.1996.855">Henry K, Acosta EP, Jochimsen E. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis. <span><span class="ref-journal">Ann Intern Med. </span>1996;<span class="ref-vol">124</span>:855.</span> [<a href="/pubmed/8610958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8610958</span></a>]<div><i>(Two nurses receiving zidovudine and zalcitabine for prevention of HIV infection after accidental needlestick for 3 weeks had fever, rash and nausea and liver test abnormalities, resolving rapidly with stopping drugs).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.chartonbain.1997.979">Charton-Bain MC, Flamant M, Aubertin JM, Belair MF, Gilquin J, Kazatchkine M, Bruneval P. <span><span class="ref-journal">Gastroenterol Clin Biol. </span>1997;<span class="ref-vol">21</span>:979–81.</span> [Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine] [<a href="/pubmed/9587562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9587562</span></a>]<div><i>(33 year old man with HIV infection developed lactic acidosis 8 months after starting zidovudine [pH 7.25, lactate 8 mmol/L, ALT and Alk P normal], with biopsy showing marked steatosis and abnormal mitochondria).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.sundar.1997.1425">Sundar K, Suarez M, Banogon PE, Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. <span><span class="ref-journal">Crit Care Med. </span>1997;<span class="ref-vol">25</span>:1425–30.</span> [<a href="/pubmed/9267960" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9267960</span></a>]<div><i>(47 year old man and 57 year old woman with HIV infection presented with weakness and fatigue 6 and 9 months after starting zidovudine [bilirubin 2.7 and 0.8 mg/dL, ALT 85 and 109 U/L and Alk P 59 U/L], with progressive lactic acidosis and death; autopsy showed extensive hepatic steatosis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.brinkman.1998.1735">Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. <span><span class="ref-journal">AIDS. </span>1998;<span class="ref-vol">12</span>:1735–44.</span> [<a href="/pubmed/9792373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9792373</span></a>]<div><i>(Review of mitochondrial function and role of mitochondrial toxicity or depletion in the adverse side effects of nucleoside analogues).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.blanche.1999.1084">Blanche S, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacrois C, et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. <span><span class="ref-journal">Lancet. </span>1999;<span class="ref-vol">354</span>:1084–9.</span> [<a href="/pubmed/10509500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10509500</span></a>]<div><i>(Screening for mitochondrial symptoms among children born to HIV-positive mothers treated with zidovudine during pregnancy identified 6 with mitochondrial dysfunction, ages a few months to 4 years, hyperlactatemia in 5, liver enzyme elevations in 3, hyperamylasemia in 2).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.acosta.1999.421">Acosta BS, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. <span><span class="ref-journal">South Med J. </span>1999;<span class="ref-vol">92</span>:421–3.</span> [<a href="/pubmed/10219365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10219365</span></a>]<div><i>(34 year old woman with HIV infection developed nausea and weakness 1 year after starting zidovudine, with severe lactic acidosis but normal liver tests initially, progression to multiorgan failure and death, autopsy showed massive hepatomegaly and steatosis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.chariot.1999.156">Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot M, Chazaud B, Lomb&#x000e8;s A, Schaeffer A, et al.  Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. <span><span class="ref-journal">J Hepatol. </span>1999;<span class="ref-vol">30</span>:156–60.</span> [<a href="/pubmed/9927163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9927163</span></a>]<div><i>(57 year old man with HIV infection developed nausea and fatigue with progressive lactic acidosis and death 6 months after starting a second course of zidovudine [bilirubin normal, ALT 8 times ULN, Alk P normal], autopsy showing massive micro- and macro-steatosis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.sulkowski.2000.74">Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. <span><span class="ref-journal">JAMA. </span>2000;<span class="ref-vol">283</span>:74–80.</span> [<a href="/pubmed/10632283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10632283</span></a>]<div><i>(Among 298 patients with HIV infection, ALT elevations above 5 times ULN occurred in 10.4% per year during antiretroviral treatment; factors associated with ALT elevations included ritonavir [27.3%] and coinfection with either HCV or HBV; ALT with bilirubin elevations occurred in 3 patients; 2 on indinavir and all 3 with coinfection).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.velasco.2000.2526">Velasco M, Guijarro C. Elevated liver enzymes following initiation of antiretroviral therapy. <span><span class="ref-journal">JAMA. </span>2000;<span class="ref-vol">283</span>:2526–7.</span> [<a href="/pubmed/10815112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10815112</span></a>]<div><i>(Letter in response to Sulkowski et al. [JAMA 2000] pointing out that antiretroviral therapy can cause immune reconstitution and flares of hepatitis B or C, which may be misdiagnosed as hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.sulkowski.2000.2526">Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Elevated liver enzymes following initiation of antiretroviral therapy. <span><span class="ref-journal">JAMA. </span>2000;<span class="ref-vol">283</span>:2526–7.</span> [<a href="/pubmed/10815113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10815113</span></a>]<div><i>(Reply to Velasco and Guijarro pointing at that the majority of the ALT elevations described could not be attributed to immune reconstitution).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.pai.2000.1135">Pai VB, Koranyi K, Nahata MC. Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection. <span><span class="ref-journal">Pharmacotherapy. </span>2000;<span class="ref-vol">20</span>:1135–40.</span> [<a href="/pubmed/10999509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10999509</span></a>]<div><i>(9 year old boy with HIV infection and multiple complications developed fever, thrombocytopenia and hepatitis 2 months after starting zidovudine, lamivudine and ritonavir, with progressive liver failure and severe bleeding after liver biopsy; difficult to assign specific causality to a specific agent).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.hill.2001.909">Hill JB, Sheffield JS, Zeeman GG, Wendel GD Jr. Hepatotoxicity with antiretroviral treatment of pregnant women. <span><span class="ref-journal">Obstet Gynecol. </span>2001;<span class="ref-vol">98</span>:909–11.</span> [<a href="/pubmed/11704198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11704198</span></a>]<div><i>(Two cases, 28 year old woman on zidovudine, lamivudine and efavirenz developed jaundice at 18 weeks gestation [bilirubin 20.3 mg/dL, ALT 421 U/L], remaining jaundiced until delivered at 27 weeks, resolving within 5 months after delivery; 22 year old woman started on lamivudine, zidovudine and nelfinavir at 14 weeks gestation and developed jaundice 10 weeks later [bilirubin 8.9 mg/dL, ALT 1598 U/L], progressing to acute liver failure and death).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.john.2001.717">John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. <span><span class="ref-journal">AIDS. </span>2001;<span class="ref-vol">15</span>:717–23.</span> [<a href="/pubmed/11371686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11371686</span></a>]<div><i>(349 patients with HIV infection were screened for lactate levels on multiple occasions; 2 had lactic acidosis and both were symptomatic and on stavudine: estimated incidence of 3.9 per 1000 person years).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.church.2001.748">Church JA, Mitchell WG, Gonzalez-Gomez I, Christensen J, Vu TH, Dimauro S, Boles RG. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:748–51.</span> [<a href="/pubmed/11343055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11343055</span></a>]<div><i>(2 year old boy treated for 18 months with didanosine, zidovudine and nelfinavir developed lactic acidosis and hepatic failure [bilirubin 30.6 mg/dL, AST 224 U/L], resolving slowly with stopping drugs).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.coghlan.2001.1914">Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. <span><span class="ref-journal">Clin Infect Dis. </span>2001;<span class="ref-vol">33</span>:1914–21.</span> [<a href="/pubmed/11692304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11692304</span></a>]<div><i>(Experience with 12 cases of lactic acidosis in patients with HIV infection seen over 6 years, typically with anorexia, nausea and weight loss for several weeks, AST variably elevated, 11 on stavudine, 9 didanosine, 1 zidovudine alone; 6 with pancreatitis, 6 having liver biopsies all showed macro- and micro-steatosis; five died).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.clark.2002.295">Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA, Cramp ME. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. <span><span class="ref-journal">J Hepatol. </span>2002;<span class="ref-vol">36</span>:295–301.</span> [<a href="/pubmed/11830344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11830344</span></a>]<div><i>(6 patients with HIV infection who developed acute liver failure on stavudine [n=5], lamivudine [n=3], didanosine [n=2], saquinavir [n=2], efavirenz [n=2], nevirapine [n=2], or nelfinavir, delavirdine or zidovudine [n=1] for 1-3 months [peak bilirubin 2.7-32 mg/dL, AST 240-8650 U/L, Alk P 122-191 U/L]; 2 with signs of hypersensitivity; two with hepatitis B; 5 died, autopsies showing massive necrosis; one with massive steatosis; likely multiple causes).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.hillaire.2002.275">Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D, Valla D, et al.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. <span><span class="ref-journal">Gut. </span>2002;<span class="ref-vol">51</span>:275–80.</span> [<a href="/pmc/articles/PMC1773310/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1773310</span></a>] [<a href="/pubmed/12117894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12117894</span></a>]<div><i>(Among 28 cases of NCPH diagnosed between 1994 and 1998, none were diagnosed with HIV infection and no discussion of drug relatedness; 12 had a prothrombotic disorder).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.falc_.2002.838">Falc&#x000f3; V, Rodr&#x000ed;guez D, Ribera E, Mart&#x000ed;nez E, Mir&#x000f3; JM, Domingo P, Diazaraque R, et al.  Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. <span><span class="ref-journal">Clin Infect Dis. </span>2002;<span class="ref-vol">34</span>:838–46.</span> [<a href="/pubmed/11850865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11850865</span></a>]<div><i>(Between 1997-2000, 12 cases of lactic acidosis in HIV-infected patients identified at 4 hospitals in Spain; ~1:1000 patient-years of treatment; all were receiving nucleoside analogues for 1-36 months; 1 case attributed to zidovudine, 11 to stavudine [1 also on didanosine], ALT 30-524 U/L, 33% fatality rate).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.spengler.2002.283">Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity&#x02014;a challenge for the hepatologist? <span><span class="ref-journal">J Hepatol. </span>2002;<span class="ref-vol">36</span>:283–94.</span> [<a href="/pubmed/11830343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11830343</span></a>]<div><i>(Review of the diagnosis of drug induced liver disease in patients with HIV on antiretroviral agents, with discussion of mechanisms including mitochondrial toxicity and hypersensitivity reactions).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.koch.2003.135">Koch RO, Graziadei IW, Zangerle R, Romani N, Maier H, Vogel W. Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV. <span><span class="ref-journal">Wien Klin Wochenschr. </span>2003;<span class="ref-vol">115</span>:135–40.</span> [<a href="/pubmed/12674693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12674693</span></a>]<div><i>(HIV-positive woman taking stavudine and didanosine for 18 months developed lactic acidosis with renal and hepatic failure, but recovered with stopping agents; liver biopsy showed microvesicular steatosis and giant mitochondria).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.bonnet.2003.1324">Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, Gemain MC, Malvy D, et al.  Risk factors for lactic acidosis in HIV-1-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. <span><span class="ref-journal">Clin Infect Dis. </span>2003;<span class="ref-vol">36</span>:1324–8.</span> [<a href="/pubmed/12746780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12746780</span></a>]<div><i>(Case control study of 9 patients [5 women] with HIV infection and lactic acidosis, 6 with hepatomegaly, 5 with jaundice, 8 on stavudine, 7 on didanosine, 6 on zidovudine; 6 died; risk factors were renal insufficiency and low CD4 counts, but numbers of cases were few).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.arenaspinto.2003.340">Arenas-Pinto A, Grant AD, Edwards S, Weller IVD. Lactic acidosis in HIV-1 infected patients: a systematic review of published cases. <span><span class="ref-journal">Sex Transm Infect. </span>2003;<span class="ref-vol">79</span>:340–3.</span> [<a href="/pmc/articles/PMC1744718/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1744718</span></a>] [<a href="/pubmed/12902594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12902594</span></a>]<div><i>(Review of 217 published cases of lactic acidosis; 53% female, all were taking at least one nucleoside for 1-36 months, 61% on stavudine, 33% didanosine, 31% zidovudine, 30% lamivudine; 92% had hepatic steatosis on biopsy or autopsy; 48% died).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.lonergan.2003.2495">Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. <span><span class="ref-journal">AIDS. </span>2003;<span class="ref-vol">17</span>:2495–9.</span> [<a href="/pubmed/14600521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14600521</span></a>]<div><i>(12 patients with HIV infection on antiretrovirals who developed hyperlactatemia &#x0003e;5 mmol/L [2 with acidosis; all on stavudine] stopped therapy and improved, restarting nucleosides without stavudine was tolerated in all but one case [on zidovudine], who later tolerated lamivudine and abacavir).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.kontorinis.2003.36">Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. <span><span class="ref-journal">AIDS Rev. </span>2003;<span class="ref-vol">5</span>:36–43.</span> [<a href="/pubmed/12875106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12875106</span></a>]<div><i>(Review of hepatotoxicity of antiretroviral drugs; definition of hepatotoxicity in antiretroviral studies; grade 1=1.25-2.5 times, grade 2=2.6-5 times, grade 3=5.1-10 times and grade 4=&#x0003e;10 times ULN or baseline ALT values; abacavir and lamivudine are least likely to cause hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ogedegbe.2003.329">Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. <span><span class="ref-journal">Lancet Infect Dis. </span>2003;<span class="ref-vol">3</span>:329–37.</span> [<a href="/pubmed/12781504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12781504</span></a>]<div><i>(Review of mechanisms of hyperlactatemia with antiretroviral therapy, occurs mostly with use of nucleoside analogues, stavudine, didanosine and zidovudine, attributed to mitochondrial depletion, but other mechanisms may be involved).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ofotokun.2003.55">Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. <span><span class="ref-journal">Top HIV Med. </span>2003;<span class="ref-vol">11</span>:55–9.</span> [<a href="/pubmed/12717043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12717043</span></a>]<div><i>(Review of sex differences in adverse events; higher frequency of mitochondrial toxicity and hypersensitivity in women than men).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ogedegbe.2003.475">Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. <span><span class="ref-journal">Clin Liver Dis. </span>2003;<span class="ref-vol">7</span>:475–99.</span> [<a href="/pubmed/12879995" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12879995</span></a>]<div><i>(Review of hepatotoxicity of antiretrovirals; ALT elevations above 5 times ULN reported in 7% with zidovudine, 16% didanosine, 9-13% stavudine, &#x0003c;1% lamivudine, tenofovir and abacavir, 3-10% protease inhibitors, 10% nevirapine and 8% efavirenz; recommend monitoring at 4 weeks and then every 12 weeks, stopping if ALT levels are &#x0003e;10 times ULN or if symptoms of liver injury are present, monitoring more closely if ALT levels are elevated).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.abrescia.2005.3697">Abrescia N, D&#x02019;Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. <span><span class="ref-journal">Curr Pharm Des. </span>2005;<span class="ref-vol">11</span>:3697–710.</span> [<a href="/pubmed/16305505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16305505</span></a>]<div><i>(Review of hepatotoxicity of antiretrovirals; major syndrome with nucleoside analogues is mitochondrial injury with lactic acidosis and severe hepatomegaly and steatosis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.jain.2007.615">Jain MK. Drug-induced liver injury associated with HIV medications. <span><span class="ref-journal">Clin Liver Dis. </span>2007;<span class="ref-vol">11</span>:615–39.</span> vii-viii. [<a href="/pubmed/17723923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17723923</span></a>]<div><i>(Review of hepatotoxicity of antiretroviral medications; ALT elevations occur in 2-18% of patients, but often resolve spontaneously even without dose modification; classes of injury include hypersensitivity [nevirapine, efavirenz, abacavir], mitochondrial injury [stavudine, didanosine, zidovudine], flares of hepatitis B [lamivudine, emtricitabine, tenofovir], flares of hepatitis C [any potent regimen], idiosyncratic injury [ritonavir, nevirapine, efavirenz], cholestatic hepatitis [many agents]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.wester.2007.318">Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, et al.  Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2007;<span class="ref-vol">46</span>:318–22.</span> [<a href="/pubmed/18090299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18090299</span></a>]<div><i>(Among 650 patients starting antiretroviral therapy, 2% developed hyperlactaemia [&#x0003e;4.4 mmol/L] and 1% lactic acidosis [all female, trend towards older age and higher body mass index] all on stavudine, didanosine, and/or zidovudine; 6 died, 4 of pancreatitis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.bolhaar.2007.254">Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. <span><span class="ref-journal">Clin Infect Dis. </span>2007;<span class="ref-vol">45</span>:254–60.</span> [<a href="/pubmed/17578788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17578788</span></a>]<div><i>(Among 1735 adults with HIV infection started on antiretroviral therapy, 3% developed hyperlactatemia; 23 [1%] with lactic acidosis [22 women and 22 on stavudine, 1 on didanosine and zidovudine], 30% mortality; 44 had symptomatic hyperlactatemia [37 women, all 44 on stavudine, 3 also with didanosine], able to switch to zidovudine without recurrence, 2 of 3 relapsed on restarting stavudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.lactic_acidosis_international_study_group.2007.2455">Lactic Acidosis International Study Group.  Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. <span><span class="ref-journal">AIDS. </span>2007;<span class="ref-vol">21</span>:2455–64.</span> [<a href="/pubmed/18025882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18025882</span></a>]<div><i>(Retrospective case control study of 110 cases with hyperlactataemia vs 220 controls, identified risk factors of older age, female gender, low CD4 counts, and use of stavudine, didanosine or both).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.mallet.2007.187">Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. <span><span class="ref-journal">AIDS. </span>2007;<span class="ref-vol">21</span>:187–92.</span> [<a href="/pubmed/17197809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17197809</span></a>]<div><i>(Among 8 patients with HIV infection referred for evaluation of liver disease of unknown cause, all had nodular regenerative hyperplasia and had received didanosine [and many received stavudine or zidovudine] for 1 to 2 years [bilirubin 0.2-2.0 mg/dL, ALT 0.4-2.0 times ULN, Alk P 0.9-19.1 times ULN, platelets 71-149,000/&#x003bc;L], all had varices and 5 had ascites).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.castelnuovo.2008.133">Castelnuovo B, Nanyonjo A, Kamya M, Ocama P. Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia? <span><span class="ref-journal">Afr Health Sci. </span>2008;<span class="ref-vol">8</span>:133–4.</span> [<a href="/pmc/articles/PMC2584324/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2584324</span></a>] [<a href="/pubmed/19357764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19357764</span></a>]<div><i>(60 year old woman developed symptomatic lactatemia 19 months after starting stavudine, lamivudine and nevirapine; switching to zidovudine was followed by fall of lactate levels to normal [5.2&#x02192;1.6 mmol/L], but 10 months later levels rose again [3.7 mmol/L]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.stead.2008.937">Stead D, Osler M, Boulle A, Rebe K, Meintjes G. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. <span><span class="ref-journal">Antivir Ther. </span>2008;<span class="ref-vol">13</span>:937–43.</span> [<a href="/pubmed/19043928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19043928</span></a>]<div><i>(Retrospective analysis of 75 patients with HIV infection and symptomatic hyperlactatemia; 95% women, all on stavudine [1.7 per 100 patient-years], 71% with lactic acidosis, 12 died; 30 switched to zidovudine without recurrence).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.hammer.2008.555">Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, et al. International AIDS Society-USA.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. <span><span class="ref-journal">JAMA. </span>2008;<span class="ref-vol">300</span>:555–70.</span> [<a href="/pubmed/18677028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18677028</span></a>]<div><i>(Most recent recommendations on use of antiviral therapy in adults with HIV infection including use of recently approved agents, raltegravir, maraviroc and etravirine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.inductivoyu.2008.4">Inductivo-Yu I, Bonacini M. Highly active antiretroviral therapy-induced liver injury. <span><span class="ref-journal">Current Drug Safety. </span>2008;<span class="ref-vol">3</span>:4–13.</span> [<a href="/pubmed/18690975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18690975</span></a>]<div><i>(Review of drug induced liver injury due to antiretroviral agents).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.soriano.2008.1">Soriano V, Puoti M, Garcia-Gasc&#x000f3; P, Rockstroh JK, Benhamou Y, Barreiro P, McGovern B. Antiretroviral drugs and liver injury. <span><span class="ref-journal">AIDS. </span>2008;<span class="ref-vol">22</span>:1–13.</span> [<a href="/pubmed/18090386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18090386</span></a>]<div><i>(Review of hepatotoxicity of antiretroviral drugs with recommendations on management, stopping therapy if symptoms arise, with overt jaundice [direct bilirubin], evidence of mitochondrial toxicity, ALT &#x0003e;10 times ULN, ALT at lower levels if newly marketed agent; important to rule out other causes; problematic agents include didanosine, stavudine and zidovudine, nevirapine and efavirenz, full dose ritonavir and tipranavir).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.bae.2008.1633">Bae WH, Wester C, Smeaton LM, Shapiro RL, Lockman S, Onyait K, Thior I, et al.  Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. <span><span class="ref-journal">AIDS. </span>2008;<span class="ref-vol">22</span>:1633–40.</span> [<a href="/pmc/articles/PMC2664540/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2664540</span></a>] [<a href="/pubmed/18670224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18670224</span></a>]<div><i>(Prospective monitoring found that only 1 of 69 infants born to antiretroviral treated mothers and none of 109 infants born to drug-therapy unexposed mothers with HIV infection developed ALT elevations &#x0003e;5 times ULN during the first 7 months of life).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.kumarasamy.2008.337">Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, Balakrishnan P, Yepthomi T, Poongulali S, Flanigan TP, Solomon S, Mayer KH. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. <span><span class="ref-journal">AIDS Patient Care STDS. </span>2008;<span class="ref-vol">22</span>:337–44.</span> [<a href="/pubmed/18422462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18422462</span></a>]<div><i>(Among 3154 patients with HIV infection treated with antiretroviral agents over a 4 year period at a single center in Southern India, hepatitis occurred in 3.5% usually within the first 3 months; lactic acidosis was more common in women and was associated with stavudine use).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.van_dyke.2008.1599">Van Dyke RB, Wang L, Williams PL. Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. <span><span class="ref-journal">J Infect Dis. </span>2008;<span class="ref-vol">198</span>:1599–608.</span> [<a href="/pmc/articles/PMC2737265/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2737265</span></a>] [<a href="/pubmed/19000014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19000014</span></a>]<div><i>(Among 2233 children receiving two nucleoside reverse-transcriptase inhibitors, 0.6-1.6% developed hepatitis, 8.3-13.5% acidosis; overall ALT elevations were rare [&#x0003c;1%]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 7 were attributed to antiretroviral agents, 2 nevirapine, 1 efavirenz and 4 miscellaneous combinations).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ingiliz.2009.3">Ingiliz P, Benhamou Y. Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications? <span><span class="ref-journal">J HIV Ther. </span>2009;<span class="ref-vol">14</span>:3–7.</span> [<a href="/pubmed/19731558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19731558</span></a>]<div><i>(Review of the causes of serum enzyme elevations during antiretroviral therapy; nucleoside reverse transcriptase inhibitors are capable of causing lactic acidosis, most commonly with zalcitabine, didanosine, stavudine and zidovudine; abacavir has been linked to hypersensitivity reactions and rare instances of hepatic failure).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ferrajolo.2010.721">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2010;<span class="ref-vol">70</span>:721–8.</span> [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, 3 antiretroviral agents were among the top 40 cases, including zidovudine [8th, 106 cases], lamivudine [26th, 45 cases] and nevirapine [36th, 37 cases]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury and 4 to antiretroviral agents, including 3 to combinations with stavudine and 1 to abacavir).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.schiano.2011.231">Schiano TD, Uriel A, Dieterich DT, Fiel MI. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. <span><span class="ref-journal">Virchows Arch. </span>2011;<span class="ref-vol">458</span>:231–5.</span> [<a href="/pubmed/21057809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21057809</span></a>]<div><i>(45 year old man with HIV infection developed abnormal liver tests 4 years after starting didanosine [bilirubin normal, ALT 87 U/L, Alk P 286 U/L], biopsy showing nodular regeneration which progressed despite stopping and 5 years later he presented with varices and hepatomegaly [bilirubin 1.0 mg/dL, ALT 43 U/L, Alk P 166 U/L, platelets 104,000/&#x003bc;L]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.lopezdelgado.2012.122">Lopez-Delgado JC, Mendiluce RM, Pinol TS, Fern&#x000e1;ndez XP, Sanchez L, Vicente RG. Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature. <span><span class="ref-journal">Ann Transplant. </span>2012;<span class="ref-vol">17</span>:122–7.</span> [<a href="/pubmed/22466918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22466918</span></a>]<div><i>(40 year old woman developed fever and jaundice 4 weeks after switching nevirapine for lopinavir/ritonavir in a antiretroviral regimen [bilirubin 5.0 mg/dL, ALT 5200 U/L, GGT 258 U/L, INR 4.5], with progressive hepatic failure and successful liver transplant 3 days later).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.nielsensaines.2012.2368">Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, et al.  NICHD HPTN 040/PACTG 1043 Protocol Team. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">366</span>:2368–79.</span> [<a href="/pmc/articles/PMC3590113/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3590113</span></a>] [<a href="/pubmed/22716975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22716975</span></a>]<div><i>(Controlled trial of 3 zidovudine based regimens for newborns of HIV infected mothers found ALT elevations above 3 times ULN in 14% of those receiving zidovudine alone, but none developed clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.agu.2013.117">Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. <span><span class="ref-journal">Perspect Clin Res. </span>2013;<span class="ref-vol">4</span>:117–24.</span> [<a href="/pmc/articles/PMC3700325/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3700325</span></a>] [<a href="/pubmed/23833736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23833736</span></a>]<div><i>(Among 1119 adverse drug reactions reported among HIV treated subjects in Nigeria, only 2 [0.1%] were due to hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.pugi.2013.1039">Pugi A, Bonaiuti R, Maggini V, Moschini M, Tuccori M, Leone R, Rossi M, et al.  Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database. <span><span class="ref-journal">Am J Health Syst Pharm. </span>2013;<span class="ref-vol">70</span>:1039–46.</span> [<a href="/pubmed/23719881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23719881</span></a>]<div><i>(Among 863 spontaneous reports of a drug reaction to antiviral agents over a 22 year period in Italy, 11 were due to lactic acidosis, mostly due to stavudine; zidovudine was most commonly linked to anemia).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.vispo.2013.1117">Vispo E, Cevik M, Rockstroh JK, Barreiro P, Nelson M, Scourfield A, Boesecke C, et al. European Network of Clinical Trials (NEAT).  Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. <span><span class="ref-journal">Clin Infect Dis. </span>2013;<span class="ref-vol">56</span>:1117–22.</span> [<a href="/pubmed/23315321" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23315321</span></a>]<div><i>(Case control study of 22 HIV infected patients with noncirrhotic portal hypertension [NCPH] and 58 controls for single nucleotide polymorphisms in genes for enzymes involved in purine metabolism identified 2 single nucleotide polymorphisms in the 5-nucleotidase and 2 in the xanthine oxidase genes associated with presence of NCPH).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.verheij.2013.1083">Verheij J, Schouten JN, Komuta M, Nevens F, Hansen BE, Janssen HL, Roskams T. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. <span><span class="ref-journal">Histopathology. </span>2013;<span class="ref-vol">62</span>:1083–91.</span> [<a href="/pubmed/23600724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23600724</span></a>]<div><i>(Histological analysis of 70 patients with NCPH, 13 with HIV infection who were more likely to have NRH [93% vs 46%] and who had a similar risk for underlying thrombophilic condition [31% vs 40%]).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.kupiec.2014.570">Kupiec KE, Johnson JW, Barroso LF, Wrenn RH, Williamson JC. Zidovudine as modern day salvage therapy for HIV infection. <span><span class="ref-journal">AIDS Patient Care STDS. </span>2014;<span class="ref-vol">28</span>:570–4.</span> [<a href="/pmc/articles/PMC4216478/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4216478</span></a>] [<a href="/pubmed/25365419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25365419</span></a>]<div><i>(In a retrospective analysis of safety and efficacy of salvage therapy including zidovudine in 69 patients with HIV infection, adverse events included nausea and diarrhea, but there were no instances of lactic acidosis or lipodystrophy).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.cooper.2014.717">Cooper DA, Heera J, Ive P, Botes M, Dejesus E, Burnside R, Clumeck N, et al.  Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. <span><span class="ref-journal">AIDS. </span>2014;<span class="ref-vol">28</span>:717–25.</span> [<a href="/pmc/articles/PMC3940293/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3940293</span></a>] [<a href="/pubmed/24983542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24983542</span></a>]<div><i>(In a 5 year follow up of studies comparing maraviroc to efavirenz combined with zidovudine and lamivudine, ALT levels greater than 5 times ULN occurred in 8 [2.2%] on maraviroc and 5 [1.4%] on efavirenz, about half of whom also had bilirubin elevations, but none of whom died of liver failure).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.sood.2014.55">Sood A, Castrej&#x000f3;n M, Saab S. Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review. <span><span class="ref-journal">World J Hepatol. </span>2014;<span class="ref-vol">6</span>:55–63.</span> [<a href="/pmc/articles/PMC3953810/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3953810</span></a>] [<a href="/pubmed/24653794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24653794</span></a>]<div><i>(A review of the literature on nodular regenerative hyperplasia in HIV infected patients).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.parikh.2014.734">Parikh ND, Martel-Laferriere V, Kushner T, Childs K, Vachon ML, Dronamraju D, Taylor C, et al.  Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. <span><span class="ref-journal">J Infect Dis. </span>2014;<span class="ref-vol">209</span>:734–8.</span> [<a href="/pubmed/23911709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23911709</span></a>]<div><i>(Comparison of 35 HIV infected persons with NCPH to 68 controls identified multiple clinical differences; authors propose a diagnostic algorithm that includes exposure to didanosine, splenomegaly, low platelet count or serum enzyme elevations as suggestive of diagnosis and warranting further evaluation).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 5 of which [3%] were attributed to antiretroviral agents including nevirapine, zidovudine and lamivudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.yajima.2014.582">Yajima K, Uehira T, Otera H, Koizumi Y, Watanabe D, Kodama Y, Kuzushita N, et al.  A case of non-cirrhotic portal hypertension associated with anti-retroviral therapy in a Japanese patient with human immunodeficiency virus infection. <span><span class="ref-journal">J Infect Chemother. </span>2014;<span class="ref-vol">20</span>:582–5.</span> [<a href="/pubmed/25034388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25034388</span></a>]<div><i>(35 year old Japanese woman with HIV infection presented with ascites and gastrointestinal bleeding 4 years after stopping a 5 year course of didanosine [bilirubin 0.2 mg/dL, ALT 82 U/L, AST 83 U/L, Alk P 268 U/L, platelets 207,000 /&#x000b5;L, TE=9.3 kPa, biopsy showing no cirrhosis], with improvement and resolution of ascites and abnormal liver tests after control of bleeding and avoidance of nucleoside analogs).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.brescini.2014.e15426">Brescini L, Orsetti E, Gesuita R, Piraccini F, Marchionni E, Staffolani S, Castelli P, et al.  Evaluating liver fibrosis by transient elastometry in patients with HIV-HCV coinfection and monoinfection. <span><span class="ref-journal">Hepat Mon. </span>2014;<span class="ref-vol">14</span>:e15426. </span> [<a href="/pmc/articles/PMC4199183/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4199183</span></a>] [<a href="/pubmed/25337140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25337140</span></a>]<div><i>(Among 354 adults undergoing transient elastography (TE), abnormal stiffness was found in 13% with HIV infection alone, 39% with HCV infection alone and 51% with both; treatment with stavudine and didanosine being associated with higher TE scores).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.turon.2015.556">Turon F, Silva-Junior G, Hernandez-Gea V, Garcia-Pagan JC. Hipertensi&#x000f3;n portal idiop&#x000e1;tica no cirr&#x000f3;tica. <span><span class="ref-journal">Gastroenterol Hepatol. </span>2015;<span class="ref-vol">38</span>:556–62.</span> [Idiopathic non-cirrhotic portal hypertension] Spanish. [<a href="/pubmed/26321321" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26321321</span></a>]<div><i>(Review of noncirrhotic portal hypertension including epidemiology, pathogenesis, clinical presentation and management).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.arora.2015.20140653">Arora A, Sarin SK. Multimodality imaging of obliterative portal venopathy: what every radiologist should know. <span><span class="ref-journal">Br J Radiol. </span>2015;<span class="ref-vol">88</span>:20140653. </span> [<a href="/pmc/articles/PMC4614245/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4614245</span></a>] [<a href="/pubmed/25514699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25514699</span></a>]<div><i>(Review of the radiologic findings of noncirrhotic portal hypertension that accompanies obliterative portal venopathy; typical findings being increased spleen size and stiffness with normal or shrunken liver, portal vein enlargement and varices).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ioannou.2015.577">Ioannou GN, Bryson CL, Weiss NS, Boyko EJ. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2015;<span class="ref-vol">27</span>:577–84.</span> [<a href="/pubmed/25769096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25769096</span></a>]<div><i>(In an analysis of the Veterans Administration Healthcare system Clinical Care Registry, long term use of didanosine but not other antiretroviral agents was found to be a risk factor for cirrhosis in patients with HIV monotherapy in contrast to patients with HIV-HCV coinfection, in whom all long term antiretroviral therapies were risk factors for cirrhosis).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 12 cases [1.3%] were attributed to antiretroviral agents, including one to zidovudine and one to didanosine but none to stavudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.kovari.2016.ofw009">Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, et al.  Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of anti-HIV drugs study. <span><span class="ref-journal">Open Forum Infect Dis. </span>2016;<span class="ref-vol">3</span>:ofw009. </span> [<a href="/pmc/articles/PMC4767274/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4767274</span></a>] [<a href="/pubmed/26925429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26925429</span></a>]<div><i>(Among 21,495 persons observed for an average of 4-5 years in a prospective observation study of adverse events among HIV positive patients without HBV or HCV on antiretroviral therapy, 6368 [30%] developed chronically elevated liver tests [6 per 100 patient years] and risk factors included didanosine, stavudine and tenofovir therapy but not lamivudine, abacavir or most protease inhibitors).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.vilarinho.2016.1977">Vilarinho S, Sari S, Yilmaz G, Stiegler AL, Boggon TJ, Jain D, Akyol G, et al.  Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. <span><span class="ref-journal">Hepatology. </span>2016;<span class="ref-vol">63</span>:1977–86.</span> [<a href="/pmc/articles/PMC4874872/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4874872</span></a>] [<a href="/pubmed/26874653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26874653</span></a>]<div><i>(Complete exome sequencing of DNA from 8 children with idiopathic noncirrhotic portal hypertension identified an extremely rare gene variant which was homozygous in all 8 children, the gene being deoxyguanosine kinase, an enzyme required for mitochondrial DNA replication that is also inhibited by didanosine perhaps explaining its hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ryom.2016.1731">Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, El-Sadr W, et al.  D:A:D Study Group. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. <span><span class="ref-journal">AIDS. </span>2016;<span class="ref-vol">30</span>:1731–43.</span> [<a href="/pubmed/26752282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26752282</span></a>]<div><i>(Among 45,544 individuals followed for a median of 8.4 years in a prospective observation study of adverse events in patients with HIV infection on antiretroviral drugs, 209 developed end stage liver disease and 110 hepatocellular carcinoma, the combined rate being 1 per 1000 patient years; increase risk for these outcomes occurred in those with HCV and HBV infection but was also linked to long term therapy with stavudine, didanosine, and tenofovir).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.lee.2017.2324709617690742">Lee M, Izzy M, Akki A, Tanaka K, Kalia H. Nodular regenerative hyperplasia: a case of rare prognosis. <span><span class="ref-journal">J Investig Med High Impact Case Rep. </span>2017;<span class="ref-vol">5</span>:2324709617690742. </span> [<a href="/pmc/articles/PMC5405903/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5405903</span></a>] [<a href="/pubmed/28491877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28491877</span></a>]<div><i>(26 year old woman with perinatally acquired HIV infection developed splenomegaly and abnormal liver tests while on tenofovir, emtricitabine and atazanavir/ritonavir [bilirubin 0.7 mg/dL, ALT 83 U/L, AST 80 U/L, Alk P 260 U/L, platelets 72,000, INR 1.2, biopsy showing minimal fibrosis and nodular regeneration] who subsequently was found to have a hepatic mass on imaging suspected to be HCC; no mention of previous therapy with didanosine or stavudine).</i></div></div></li><li><div class="bk_ref" id="Zidovudine.REF.ahmad.2019.e17961">Ahmad AK, Atzori S, Taylor-Robinson SD, Maurice JB, Cooke GS, Garvey L. Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus. <span><span class="ref-journal">Medicine (Baltimore). </span>2019;<span class="ref-vol">98</span>:e17961. </span> [<a href="/pmc/articles/PMC6882591/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6882591</span></a>] [<a href="/pubmed/31764798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31764798</span></a>]<div><i>(Among 25 patients with HIV infection undergoing shearwave elastography, spleen stiffness was more reliable than liver stiffness in assessing noncirrhotic portal hypertension, being elevated in 6 of 11 cases of NCPH but in none of 14 controls).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548210</span><span class="label">PMID: <a href="/pubmed/31643535" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643535</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Zepatier/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Zileuton/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548210&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548210/?report=reader">PubReader</a></li><li><a href="/books/NBK548210/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548210" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548210" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Zidovudine. [Updated 2020 Jun 25].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548210/pdf/Bookshelf_NBK548210.pdf">PDF version of this page</a> (202K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Zidovudine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Zidovudine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Zidovudine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Zidovudine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4866464" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4866464" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4866464" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644004" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Stavudine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Stavudine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643550" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Abacavir</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Abacavir<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9287227" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.</a><span class="source">[N Engl J Med. 1997]</span><div class="brieflinkpop offscreen_noflow">A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">N Engl J Med. 1997 Sep 11; 337(11):725-33. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12126455" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.</a><span class="source">[Paediatr Drugs. 2002]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bhana N, Ormrod D, Perry CM, Figgitt DP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Paediatr Drugs. 2002; 4(8):515-53. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11322269" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The role of didanosine in the management of HIV-1 infection.</a><span class="source">[Antivir Ther. 1997]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The role of didanosine in the management of HIV-1 infection.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gazzard BG, Moyle GJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antivir Ther. 1997 Jul; 2(3):135-47. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643535" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643535" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=6046985ca19b7255ae8964fc">Zidovudine - LiverTox</a><div class="ralinkpop offscreen_noflow">Zidovudine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:34:20-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B2F570468FBE10000000001E60093&amp;ncbi_session=CE8B2F57046985C1_0486SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548210%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548210&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548210/&amp;ncbi_pagename=Zidovudine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B2F57046985C1_0486SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>